NPCE
NeuroPace Inc

332
Mkt Cap
$519.93M
Volume
130,327.00
52W High
$18.98
52W Low
$7.56
PE Ratio
-20.72
NPCE Fundamentals
Price
$15.47
Prev Close
$15.61
Open
$15.61
50D MA
$13.94
Beta
1.27
Avg. Volume
308,001.42
EPS (Annual)
-$0.9318
P/B
28.05
Rev/Employee
$434,271.74
Loading...
Loading...
News
all
press releases
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, Marketbeat...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS System Indication for Idiopathic Generalized Epilepsy
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S...
Business Wire·13d ago
News Placeholder
UBS Group Raises NeuroPace (NASDAQ:NPCE) Price Target to $22.00
UBS Group upped their target price on shares of NeuroPace from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday...
MarketBeat·14d ago
News Placeholder
JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price
JPMorgan Chase & Co. lifted their price target on shares of NeuroPace from $18.00 to $20.00 and gave the company an "overweight" rating in a research note on Wednesday...
MarketBeat·20d ago
News Placeholder
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of...
Business Wire·22d ago
News Placeholder
NeuroPace, Inc. $NPCE Shares Acquired by Divisadero Street Capital Management LP
Divisadero Street Capital Management LP lifted its position in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 529.2% during the 2nd quarter, according to the company in its most recent 13F...
MarketBeat·23d ago
News Placeholder
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and NeuroPace AI platform will be...
Business Wire·28d ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Trading Down 4.1% - Should You Sell?
NeuroPace (NASDAQ:NPCE) Stock Price Down 4.1% - Should You Sell...
MarketBeat·1mo ago
News Placeholder
NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been given an average rating of "Moderate Buy" by the eight ratings firms that are presently covering the company, MarketBeat Ratings...
MarketBeat·1mo ago
News Placeholder
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today announced favorable Medicare reimbursement updates for the RNS...
Business Wire·1mo ago
<
1
2
...
>

Latest NPCE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.